tyr Pharma, a tiny San Diego biotech, has snapped up a pretty broad swath of patents that “cover an entirely new area of biology,” as CEO John Mendlein puts it.

Atyr’s immune-modulating drug candidates are based on cell-signaling molecules that the company has dubbed “physiocrines,” which are thought to have evolved over billions of years to help with an organism’s homeostasis, or state of equilibrium.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Question: do they patent the protein-building enzymes themselves, or they way they produce them, and/or the way they use them?

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.